Mitochondria, potential new therapeutic targets in pancreatic cancer - CRCM PhD Day 2021 will take place on May 28 2021 - La cycline A2, qui maintient l'homéostasie du côlon, est un facteur de pronostic dans le cancer colorectal -

TrGET is a preclinical testing platform, specialized in the implementation and development of in vitro and in vivo tests to evaluate the involvement of a target gene in tumorigenesis or the biological activity of anti-tumor compounds with therapeutic potential. Significant efforts are being made in technological development aspects (development of tests, tools and proposed cellular and animal models).

The platform offers a variety of flexible and adaptable tests, based mainly on bioluminescence technology.

In vitro (96-well format):
proliferation/cytotoxicity / survival-apoptosis / clonogenicity / migration / angiogenesis /

In vivo (non-invasive intravital imaging):
tumor volume / progression or doubling time / tumor spread (blood, marrow, spleen,…) and metastasis / survival
tissue sampling, preparation and storage